posted on October 28, 2002 01:00
EMERYVILLE, CA, October 28, 2002 — Biotique Systems, Inc. today announced announced that Merck & Co., Inc. has licensed the Biotique Local Integration System (BLIS) for its worldwide drug discovery operations.
"We are delighted that Merck, a global leader in pharmaceutical research and development, has selected BLIS to support its genomic data analysis needs," said Stephen Sanders, chairman and chief executive officer of Biotique Systems, Inc.
BLIS is a data integration, analysis and visualization platform that enables pharmaceutical and biotechnology companies to expedite target discovery and refinement using the human genome as a reference template.
Biotique Systems, Inc. was founded in 2001 to solve critical issues in the life sciences. The Company provides decision support tools and services for the emerging field of pharmacogenomics. Biotique's pharmaceutical and biotechnology customers have adopted the Company's solutions to integrate their proprietary, third-party and public data sources, optimize biochip designs and other assays, and perform comparative genomic analysis. As a result, Biotique is enabling the next generation of genomic discovery.